ITGB3 and non-small cell lung carcinoma: As evidenced by the dual IHC and flow cytometry analyses, we confirmed the presence of CD61+ T cells in the CD103+ TILs population, with variable frequencies across the patients with NSCLC, ranging from 2% to 77% (Fig. 1c and Extended Data Fig. 3b).